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ABSTRACT: 
 
Companies innovation process is an important way to both achieve and sustain competitive ad-
vantage in today’s business world. The innovation happens in companies within a process con-
sisting from three processes: the front-end innovation process, the new product development 
process, and commercialization process. The innovation strategy of companies is comprised from 
different attributes that the company’s emphasis and values in their decision-making process.  
 
The theoretical framework of this thesis is built on the principles on open innovation, aggressive-
ness strategy of the companies, and holistic analytical model developed to evaluate companies’ 
strategic priorities. The open innovation is scoped by selected strategic attributes in the compa-
nies, from which the overall innovation strategy of the company is formed. 
 
This study tries to analytically model the open innovation strategy of the case companies within 
biotechnology and pharmaceutical industries. This study uses several critical factors index-based 
methods to evaluate the past experiences and future expectations of the companies’ top manage-
ment personnel around the open innovation. In addition, an analytical hierarchy process method 
is used to specify and evaluate the case companies’ overall innovation strategy around open in-
novation parameters. This study evaluates the different innovation strategy types used in high 
technology companies. This study was able to quantitatively determine the innovation strategy 
types of the case companies using the innovation strategy index method, which was originally 
derived from manufacturing strategy index method. However, no correlation around the re-
source allocation index and innovation strategy index was not found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________ 
KEYWORDS: innovation, open innovation, front-end innovation process, ana-
lytical hierarchy process, resource allocation, performance measurement
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1. INTRODUCTION 
 
The key success factor for companies in competitive settings is a flexibility to an-
swer to the customer’s needs and an ability to launch new products, which the 
market needs in given time (Skinner 1986: 55-59). This happens through an inno-
vation process that can be divided into three segments: The front-end innovation 
(FEI), the new product development (NPD) process, and commercialization 
(Koen, Bertels & Kleinschmidt 2014: 34-43). The FEI refers to the first and most 
important phase of innovation before the development and the commercializa-
tion process takes place, and in which the start and resource commitments are 
decided (Cegarra-Navarro, Reverte, Gómez-Melero & Wensley 2016: 530-539; 
Mohan, Voss & Jiménez 2017: 193-201). Accordingly, the NPD process is the 
where the actual development of the innovation happens. For successful NPD 
process, two types of knowledge are required: component knowledge and archi-
tectural knowledge. The component knowledge is about the core design concepts 
and how they are implemented in a specific component. The architectural 
knowledge instead, is about the knowledge of design by which the specific com-
ponents are linked to other components in a coherent way (Henderson & Clark 
1990: 9-30). 
 
The company has sustainable competitive advantage (SCA) when it is imple-
menting a value creating strategy that is simultaneously not implemented by any 
other of its current or potential competitors, because they are unable to reproduce 
the same strategy for their benefit. In the resource-based view (RBV) in order to 
achieve the full potential of SCA, the resources of the company must meet the 
following four attributes: it must be valuable when exploiting opportunities, it 
must be rare among the company’s current and potential competition, it must be 
inimitable, and the resources needs to be non-substitutable for other non-rare re-
sources (Barney 1991: 99-120). Furthermore, the resources can be categorized into 
tangible and intangible resources (Caves 1980: 64). Tangible resources are ex-
haustible physical objects, such as land or properties (Wernerfelt 1989: 4-12). 
These resources are protected by normal property rights and therefore easy to 
replicate by current or potential competitors. However, intangible resources are 
inexhaustible where the use by one does not prevent others from using the same 
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1.1. Objective of the thesis 
 
Earlier research indicates that OI strategies have had a positive effect related to 
firm’s innovation performance because of their tendency to lower the barriers of 
innovations which results from the size of the company (Brem et al 2017). The 
recent studies of OI have extended to variety of areas, such as small and medium-
sized enterprises (SMEs), non-profit organizations (NGOs), new units of analysis, 
and different companies in high-technology and low-technology industries 
(Bogers, Chesbrough & Moedas 2018: 5-16). However, there is a lack of research 
how quantitatively evaluate the state of the OI strategies in companies. Therefore, 
this thesis is conducted to observe the performance of innovation and attempts 
to find answers to following research questions (RQ): 
 
RQ1: Is there a correlation between innovation strategy and resource allocation 
profiles? 
RQ2: Can innovation strategy be defined and evaluated in terms of SCA? 
RQ3: Can innovation strategy be analytically modelled based on strategic priori-
ties of technology, knowledge, development, and co-operation? 
 
In order to answer to the RQs presented above, this thesis examines the general 
characteristics of innovation by defining variant types of innovation. After the 
theoretical foundation and qualitative characteristics are identified, the RQ1 and 
RQ2 are answered with the quantitative methods applied to empirical data gath-
ered for this study. The answer to the RQ3 is gathered, verified, validated 
through interviews of the case companies. 
 
 
1.2. Structure of the thesis 
 
The structure of this study is organized as follows: it consists of ten main chapters 
which start with an introduction and framework, and continues to review the 
relevant literature, context, overview of the case companies, and methodology in 
order to provide necessary background for the case studies. 
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In the introduction, general background for the thesis is described with objectives 
and research questions. The framework for the study is described in the second 
chapter and sufficient literature review about the issues connected to the research 
are described in the third chapter. In chapter four and chapter five the environ-
ment of the case companies and the case companies itself are described in order 
to provide background where the study subjects operate. 
 
In chapters six, seven, and eight the methodology, relevant results, and analysis 
of the study are described and analyzed. In chapter nine there are discussion 
about how the results and analysis of the result should be interpreted, and in the 
final chapter ten there are conclusion about the study results with recommenda-
tions for the future research. 
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3. LITERATURE REVIEW 
 
The definition of innovation varies greatly in existing scientific literature (Dzi-
allas & Blind 2018: 3-29). The objective of innovations is to create tangible value 
by implementing commercially viable solutions to customers’ needs, problems, 
and business opportunities (Racheria 2016: 25-52). Innovations can be considered 
as one of the key factors for the SCA of a company in the competitive global en-
vironment. The patterns of innovations can be categorized into product innova-
tions and process innovations (Freeman & Soete 1997: 242-264). Companies that 
innovate are more capable of responding to the surrounding challenges faster 
compared to the companies that are not able to innovate (Cegarra-Navarro et al 
2016). The SCA is obtained by offering greater value compared to competitors, 
either by more affordable prices or by providing more innovative products, 
which enable higher sales prices. It may also include enhanced access to re-
sources, such as tacit knowledge in form of highly skilled labour, or access to the 
leading-edge technology. 
 
To achieve the SCA, companies should have efficient operational strategy that 
helps them to allocate their resources properly. Initially four different strategy 
types have been categorized based on the strategy aggressiveness: prospector, 
analyser, defender, reactor (table 1). In the prospector strategy the company 
drives to be a market leader through innovations. In the defender strategy the 
company seeks profit from core customers with low cost-structure in order to 
establish a stable market position. In contrast, the analyser strategy is a combina-
tion of the prospector and the defender strategy. The reactor strategy is usually 
not classified as a strategy, but it is targeted for situations that need rapid re-
sponding (Miles, Snow, Meyer & Coleman 1978: 546-562). 
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types of OI: outside-in strategy and inside-out strategy. These are also referred to 
as inbound and outbound OI strategies, respectively (Bogers et al 2018). These 
two strategies can be further categorized in to pecuniary and non-pecuniary seg-
ments (table 2) based on the type of financial compensation they possess (Bus-
arovs 2013: 103-119). In the abundant knowledge landscape, companies must or-
ganize their internal R&D functions to identify, to understand, to select, and to 
connect to the profusion of available external knowledge. Internal R&D is also 
needed to fulfil the components of externally developed knowledge needed for 
the company’s own processes. Nevertheless, the strategies of companies change 
nowadays faster than the basic research. Therefore, companies should not wait 
for the technologies they need to arrive. Instead, they should gain access to the 
technology as soon as possible: either from internal sources or from external 
sources. Companies can also generate additional incomes by selling their internal 
R&D outputs to other companies to be used in their systems and platforms (b. 
Chesbrough 2003). 
 
Table 2. Subtypes of open innovation based on financial compensation 
(Adapted from Chesbrough & Brunswicker 2014: 16-25). 
 Pecuniary Non-pecuniary 
O
u
ts
id
e-
in
 In-licensing technologies 
Contract R&D services 
University research grants 
Start-up competitions 
Co-creation with customers 
Crowdsourcing 
Publicly funded R&D consortiums 
Informal networking 
In
si
d
e-
ou
t Spinoff technologies 
Market-ready products 
Out-licensing technologies 
Joint ventures 
Public standardization 
Donations to NGOs 
 
In most cases the non-pecuniary outside-in and inside-out OI strategies can be 
categorized as coupled OI strategy because of its aim for joined innovation and 
exploitation with mutual benefit (Gassman & Enkel 2004: 1-18). In practice the 
coupled OI strategy is a combination of the outside-in and inside-out OI strate-
gies (figure 6), which happens through the inflows and outflows of knowledge 
(Lameras 2015: 1-51). 
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3.2.1. Outside-in open innovation strategy 
 
In the outside-in OI strategy, company choose to integrate external knowledge in 
to its internal innovation process. This can be achieved through customer and 
supplier integration, investing in global knowledge creation, buying or licensing 
external IPR. The in-licensing has proven to be a fast, relatively low risk, and 
inexpensive alternative to gain access to new external technologies. Companies 
take part of outside-in OI operations usually because their need for knowledge 
or technology are not met with internal capacities. Gassman & Enkel (2004) state 
that outside-in OI strategy is primarily used in low-technology industries for sim-
ilar technology acquisition from high-technology industries in form of “spillo-
vers”. However, outside-in OI strategy is also widely used in high-knowledge 
intensity industries such as biotechnology and pharmaceutical industries 
(Gassman & Enkel 2004). 
 
From the OI strategies described in chapter 3.2, the outside-in OI strategy is the 
most common type of OI (Chesbrough & Brunswicker 2014). This aspect has also 
received the greatest attention in both academic research and in industry practice 
(Bogers et al 2018). As the outside-in OI strategy consist of opening the compa-
nies’ internal R&D processes to external inputs, it has been suggested that out-
side-in strategy could bring value in at least three following cases (Bogers et al 
2018; Gassman & Enkel 2004): 
1) lack of internal resources, 
2) better external technology position, and 
3) easier transferability of external technology or knowledge and low-barrier 
market-entry. 
 
Main reason for underutilization of outside-in OI strategy is the “Not-Invented-
Here” (NIH) syndrome, in which the companies are unwilling to use external 
knowledge only because it is not invented in-house. This happens especially at 
the early stage of companies’ OI programs, but it tends remain important reason 
over the time as well (Chesbrough & Brunswicker 2014). In order for companies 
to use outside-in OI strategy, they need to invest in their internal innovation ac-
tivities as well, because at the end it is the internal competence which enables 
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companies to access to external ideas, knowledge, and technologies (Hung & 
Chou 2013:  368-380; Christensen, Olesen & Kjær 2005: 1533-1549). This also ex-
plains why some companies are more capable of using outside-in OI strategy 
than others (Pihlajamaa 2018: 37). 
 
3.2.2. Inside-out open innovation strategy 
 
Compared to the outside-in OI strategy, the inside-out OI strategy is far less ex-
plored in both industry practices and academic research. The inside-out OI re-
quires companies to have a process to allow untapped and underutilized ideas 
and technologies to flow outside the company for the use of others in their busi-
ness stragegy and core operations (Bogers et al 2018). In the inside-out OI strategy 
companies focus on externalising their own knowledge and innovation in order 
to commercialize them faster compared to their internal NPD funnel (Gassmann 
& Enkel 2004). 
 
Inside-out operations happens in three major ways: out-licensing, technology 
spinoffs, and divestments. From these the out-licensing of technology or other 
knowledge is the most common in the inside-out OI strategy. Most of the com-
panies are unable to fully capitalize their own technological knowledge inter-
nally, and therefore the technology out-licensing allows them to capture addi-
tional value from this knowledge (Lichtenthaler 2010: 429-435). However, strong 
patent protection has no direct connections to the performance of inside-out OI 
strategy. The higher the patent protection is, the higher the transaction rate for 
the technology in the markets is as well (Lichtenthaler 2009: 38-54). The other 
forms of inside-out OI strategies include technology spinoffs, where usually for-
mer employees establish their own companies around the technology that is not 
needed in the company that originally developed it. Supporting this through di-
rect investments can generate strategic benefits to the parent company of the 
technology. Additionally, the divestments use the same method as the technol-
ogy spinoff model with the exception that the outsourced technology is either 
sold as a whole (pecuniary method) or leaves the parent company without any 
transactions (non-pecuniary method) usually because the technology has been 
neglected in the parent company. 
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The relationship between IPR and OI is controversial because the IPR prevents 
and promotes OI at the same time, even though in overall the goal of the IPR is 
to insure and encourage companies to invest in innovations. Nevertheless, the 
IPR offers opportunities through OI to scale the R&D activities, which would not 
be otherwise feasible without these protection options (Brem et al 2017). On the 
other hand, “Not-Sold-Here” (NSH) syndrome includes a negative attitude, 
which are very similar compared to the transfer of companies’ internal technolo-
gies in NIH. The fear in NSH towards the inside-out OI strategy arise from a fear 
of strengthening competitors by selling technologies and innovations of the com-
pany to its competitors. The NSH syndrome becomes stronger along with lack of 
experience in inside-out technology transfer and ineffective markets for techno-
logical knowledge.  Focusing only on internally developed technologies may also 
result for a limited exploitation of companies’ own technology base (Lichten-
thaler, Hoegl & Muethel 2011: 45-48). 
 
By changing the locus of exploitation of innovations to outside the company, en-
ables companies to generate revenue and profits by licensing or selling their IPR 
and multiplying their technologies to other companies. The use of the inside-out 
OI strategy also offers opportunities for alternative markets to companies using 
this strategy. Other benefits of using the inside-out strategy includes complemen-
tary knowledge, when gaining access to other markets, reducing time-to-market 
of internal ideas, when they do not have to be hold on reserve, and the possibility 
to concentrate on core competencies of the company, while sharing the cost via 
out-licensing (Gassmann & Enkel 2004). 
 
3.2.3. Coupled open innovation strategy 
 
In the coupled OI strategy the creation, exploitation, and commercialization of 
new knowledge is conducted in co-operation with one or several external collab-
orators (Cheng & Huizingh 2014: 1235-1253). The coupled OI strategy integrates 
outside-in and inside-out operations by working in collaboration in different al-
liances with complementary partners that are crucial for the success of partici-
pating companies. The collaboration happens in strategic networks. To succeed 
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in co-operation, it is in it necessary to both give and receive knowledge. The co-
operation happens usually by in joint development of knowledge in relationship 
with specific collaborators like consortia of customers, competitors, suppliers, 
joint ventures, and universities and research institutes. In most cases the co-op-
eration can be characterised by a fundamental interaction between participating 
parties over a long period of time (Gassmann & Enkel 2004). In established core 
collaboration process of innovation, companies can obtain external knowledge 
through the outside-in OI process and have their internal ideas migrate to the 
market through the inside-out OI process simultaneously (figure 6) (Lichten-
thaler & Ernst 2007: 383-397). 
 
Global biotechnology and pharmaceutical companies have formed numerous 
new alliances as the biotechnology have been seen as a significant input in phar-
maceutical R&D process. The most important success factor for these companies 
using the coupled OI strategy is an ability to re-evaluate and learn. Another im-
portant factor is the optimal balance of outside-in and inside-out operations 
within the coupled OI strategy. The companies must have imperative quality to 
integrate external knowledge into their own technology and knowledge base and 
at the same time outsource them for the benefit of the collaborators. Accordingly, 
the collaborators must be able to provide competencies that are needed to achieve 
competitive advantage in their own market (Gassmann & Enkel 2004).  
 
Compared to the linear model of innovation, where the invention follows the in-
novation and diffusion to market, a more collaborative model between academia, 
industry, and government called Triple Helix (TH) have been theorized as well 
(Etzkowitz & Leydesdorff 1995: 14-19). The main idea around the concept of TH 
model is that academia is in a key role of innovation working together with in-
dustrial and governmental agencies. The academia engages in basic research and 
prepares the core for the future innovations. The role of the government as a pol-
icy maker is to act as an enabler and regulator for the other participants in the 
model. These governmental organizations may consist of technology transfer of-
fices or industry associations. The industry is seen as producers of commercial 
goods that diffuse the innovative products to the market. However, in addition 
to these traditional tasks in TH model, each participant adopts new roles and 
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3.3. User innovation 
 
The term UI was originally coined by Eric von Hippel (1986). In the UI the inno-
vation is done by lead-users who are creating solution to fulfil an unmet need 
that does not have a commercially available solution. The user refers to interme-
diate users such as user firms, user communities, or individual end-users (Gam-
bardella, Raasch & von Hippel 2017: 1450-1468). The innovations developed by 
users can be industrial innovations, consumer product innovations, or process 
innovations (Churchill, von Hippel & Sonnack 2009: 6-26). In contrast to the tra-
ditional innovation, in the UI model the diffusion of innovations happens from 
peer-to-peer and never proceeds to commercial market as such. Therefore, the 
IPR does not apply to the user derived innovations. The benefit of the UI is only 
a solution to a known problem of individual. 
 
The UI model interacts with the traditional vertical innovation model by provid-
ing information of the design adopted from the lead-users. In addition, the tradi-
tional vertical innovation model provides innovation supports to the lead-users 
to make better UI derived products (figure 9). This interaction connects the UI to 
the external knowledge base of the OI model (figure 5). The UI brings value to 
the innovation value chain by collaboration with the lead-users, but also through 
coupled OI strategy when the proposition of innovating users is at least on mod-
erate level. However, when the proportion of innovating users are at low level, 
the innovation happens mostly through the closed innovation model (Gam-
bardella et al 2017). Furthermore, the diffusion of physical UI derived products 
to the market through manufacturers’ is still more common than information-
based lead-user innovation derived products (von Hippel 2005). 
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estimated that 85 to 95 percent of companies R&D portfolios are consisting of 
incremental innovation projects. These types of innovations exploit the existing 
technologies and shapes the existing technology to be used in some other pur-
poses as well. By this definition, the incremental innovations are innovations at 
the margin (Luecke 2009: 2-7). The incremental innovations have a tendency to 
reinforce the competitive advantage of established companies by impacting on 
their core competencies (Henderson & Clark 1990). Incremental innovations can 
be further categorized into modular innovations and architectural innovations. 
A modular innovation involves changing a module of the design in a business 
model, process, or design of the product in order to create improvements. Archi-
tectural innovations include improvement changes on how the modules are used 
in situations mentioned earlier, and how they work together bringing substantial 
improvements to the business model process or products (Pham-Gia 2011: 1-28). 
 
Incremental innovations are continuous form of innovation, which are repre-
sented in companies through continuous innovation process, idea, and innova-
tion management. Many companies concentrate on incremental innovations be-
cause it has significantly lower risk of failure and it allows companies to intro-
duce changes through a longer period of time making the adoption of innova-
tions more likely. The management of incremental innovation is described by 
transparent and static innovation process from an innovative idea to the imple-
mentation of the idea. Incremental innovations are designed to follow well de-
fined processes and responsibilities (Pham-Gia 2011). Incremental innovation 
strategy helps companies to maintain and improve their competitive advantage 
over time compared to their competitors. Conversely, companies that fail to in-
troduce incremental and sustaining innovations at regular basis will lose their 
competitive advantage. Therefore, incremental innovations are more common in 
high-technology companies, and for example consumer technology developers 
are constantly introducing new features to existing products. Accordingly, from 
the high-technology consumer market-side, people are waiting for updated 
product features as well (Oja 2010: 75-77). 
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3.5. Radical innovation 
 
RI causes drastic changes on how things are done. They establish new function-
alities and processes in companies (White & Bruton 2007: 40). RIs have a tendency 
to destroy or displace an existing business model with an entirely new business 
model by changing the components and their interactions with each other in new 
ways. RIs have elements from both incremental innovations and DIs, although 
incremental innovations and RIs can be seen as the ends of a continuum. They 
require fully novel competencies, which can displace the old competencies in 
companies. They can also be considered as breakthrough innovations that trans-
form the market essentially (Green, Gavin & Aiman-Smith 1995: 203-214). 
 
RIs can result in high level of compensation, but they include a high degree risk 
as well when compared to incremental innovations. In addition, RI includes an 
eminent resistance and slow adoption rate. Nevertheless, RIs are strategic op-
tions for companies and therefore intentional and promoted. They enable com-
panies to differentiate from their competitors by creating potential high return 
on their investment. RIs tend to create dramatic change in the companies’ pro-
cesses, their products, and services by transforming existing markets or indus-
tries, or even creating new ones. 
 
In different industries the incremental and RIs often go together with each other. 
The development of innovations is characterized by long periods of incremental 
innovations paced by random actions of RIs (figure 11). RIs take place between 
small incremental innovations which are abrupt by a technological leap forward 
in performance per cost. The incremental innovations resume after the RIs 
(Luecke 2009). RIs usually happen in complex uncertainty. To evolve RI with ex-
ternal knowledge, idea base, and technologies; companies must have capabilities 
and processes to identify and to utilize them with their existing internal 
knowledge base and company culture (Pihlajamaa 2018: 122). 
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NPD process in not only useful but may harm the companies (Henderson & Clark 
1990). This is because the incremental innovations diffuse along the mainstream 
market, where as DI commence from the low-end encroachment and diffuse up-
ward from below of the mainstream market (Schimdt & Druehl 2008: 347-369). 
Although DIs are inferior to products developed by incumbent innovations 
based on the performance, they offer a set of attributes that will benefit customers 
at the bottom of the market because they are often cheaper, smaller, more acces-
sible and more convenient. Additionally, companies utilizing incumbent innova-
tions are typically unmotivated to develop DIs that target to smaller markets, 
because the Dis provide lower margins for their current customers and services 
which they are unable to use (Christensen et al 2018). 
 
The DI can be characterized into two categories: new-market and low-end dis-
ruptions. New-market disruption begins from the niche-markets where the over-
all customer needs are gradually changed or from detached-markets, where cus-
tomer needs are thoroughly diverse (Schimdt & Druehl 2008). In majority of the 
cases the new-market DIs are targeted to the customers who does not have re-
sources to obtain the mainstream market innovations (Christensen & Raynor 
2003: 102). Correspondingly, the low-end DIs happens in the mainstream mar-
kets and are more immediate compared to the new-market DIs (Schmidt & 
Druehl 2008). The difference between RI and DI is that RI impacts the industry of 
interest by replacing existing technology with better technology, which have a 
focus and priority on a long-term objective.  The Dis however happens when 
companies start from a small market and focus to achieve short-term objectives, 
thriving on low-end market penetration. 
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4. CASE STUDY CONTEXT 
 
In this chapter the high-technology, biotechnology, and pharmaceutical indus-
tries are defined. In addition, the operations of companies functioning in those 
industries are described. 
 
 
4.1. Definition of high-technology companies 
 
The classification of technology is relative and many manufacturing operations 
in companies can be considered as high-technology operations. In addition, 
many of these companies produce variety of products that can be considered ei-
ther low-technology or high-technology products. However, when the compa-
nies are evaluated by their direct R&D intensities, they can be assessed by their 
relative R&D performance. For service industries other indicators, for example 
skill intensity, indirect R&D measures, and technology developed in investments 
can be used. The OECD industry technology intensity classification methodology 
uses three indicators in aspect of technology producers and technology users (In-
ternational Standard Industrial Classification Revision 3 Technology Intensity 
Definition 2011: 1-6): 
1) R&D expenditure per value added, 
2) R&D expenditure per production value, 
3) R&D expenditure added with technology developed in intermediate and in-
vestment goods per production value. 
 
The OECD’s categorization of manufacturing industries into high-technology, 
medium-high-technology, medium-low-technology, and low-technology seg-
ments is made after ranking the industries according to their average R&D inten-
sities (table 4). Industries, which are categorized into higher technology groups, 
have higher average technology intensities in the indicators compared to the in-
dustries in the lower technology groups. The lower technology groups include 
industries from relatively low aggregate sectors (International Standard Indus-
trial Classification Revision 3 Technology Intensity Definition 2011). 
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Table 4. Technology intensity classification of manufacturing industries 
(Adapted from International Standard Industrial Classification Revision 3 Tech-
nology Intensity Definition 2011) 
High-technology industries Medium-high-technology industries 
Aircraft and spacecraft; pharmaceuti-
cals; office, accounting, and compu-
ting machinery; radio, TV, and infor-
mation and communication technol-
ogy (ICT); medical precision, and op-
tical instruments and materials. 
Electrical machinery and apparatus; 
motor vehicles, trailers and semi-trail-
ers; chemicals excluding pharmaceuti-
cals; railroad and transport equip-
ment; machinery and equipment. 
Medium-low-technology industries Low-technology industries 
Shipbuilding and boat building and 
repairing; rubber and plastics-based 
products; coke, refined petroleum 
products and nuclear fuel; basic met-
als and fabricated metal products; 
other non-metallic mineral products. 
Manufacturing; recycling; wood, 
pulp, paper, paper derived products, 
printing and publishing; fast-moving 
consumer goods (FMCG) and tobacco; 
textiles, textile and other clothing 
products. 
 
 
4.2. Definition of biotechnology industry 
 
OECD has defined biotechnology by a single definition as: 
 
“the application of science and technology to organisms, as well as parts, products 
and models thereof, to alter living or non-living materials for the production of 
knowledge, goods and services.” 
 
This definition covers both modern biotechnology and the traditional activities 
in the industry. Therefore, a list-based definition of biotechnology is included 
with the single definition for more operational description (table 5). The list-
based definition is only indicative, and it is expected to change over time as the 
biotechnology industry evolves, but the single definition is expected to remain 
the same for a longer period of time (van Beuzekom & Arundel 2009: 9-11). 
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Table 5. The list-based definition of biotechnology (adapted from van Beuzekom & Arundel 2009). 
Category Definition 
DNA/RNA 
Genomics, pharmacogenomics, DNA probes, genetic engineering, DNA/RNA se-
quencing, synthesis, and amplification, gene expression profiling, and use of antisense 
technology. 
Proteins and other molecules 
Sequencing, synthesis, and engineering of proteins and peptides, including large mol-
ecule hormones; improved large molecule drug delivery methods; proteomics, protein 
isolation and purification, identification of cell receptors and signalling. 
Cell and tissue culture engineering 
Cell and tissue culture, tissue engineering including tissue scaffold and biomedical en-
gineering, cellular fusion, vaccine and immune stimulants, embryo manipulation. 
Process biotechnology techniques 
Fermentation using bioreactors, bioprocessing, bioleaching, biopulping, biobleaching, 
biodesulphurisation, biomediation, biofiltration and phytoremediation. 
Gene and RNA vectors Gene therapy, viral vectors. 
Bioinformatics 
Construction of databases on genomes, protein sequences; modelling complex biolog-
ical processes including systems biology. 
Nanobiotechnology 
Applies the tools and processes of nano- and microfabrication to build devices for 
studying biosystems and applications in drug delivery, diagnostics etc. 
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analysed by the share of total pharmaceutical sales. The top ten pharmaceutical 
companies account for 46 % of the global pharmaceutical sales. Accordingly, in 
pharmaceutical manufacturing the unit production costs are very low compared 
to the unit prices. This results to a very high reliance on IPR in order to protect 
the high R&D investments from competitors (Pharmaceutical Pricing Policies in 
a Global Market 2008: 51-205). 
 
Pharmaceutical industry reinvests on average 15.9 % of their sales revenue back 
to R&D. However, the R&D investments are very concentrated as the top 15 larg-
est companies accounted for 72 % of global pharmaceutical R&D investments. 
From all of the global top 1,250 firms, the pharmaceutical companies accounted 
for 19.4 % of spending on R&D. From this group two different major types of 
innovation have been discovered: incremental innovation and RI. Incremental 
innovations offer minor improvements to therapeutic benefit of the existing 
products. These includes the “me-too” pharmaceuticals, which molecule struc-
tures are novel, but the treatment for the specific disease already exists. These 
innovations comprise a major share of the R&D expenditure in the pharmaceuti-
cal industry (Pharmaceutical Pricing Policies in a Global Market 2008). The RIs 
are more valuable than incremental innovations (Sorescu, Chandy & Prabhu 
2003: 82-102). These include non-chemical entity biotherapeutics drugs and ge-
nome-based medicines for example (Schmid & Smith 2005: 50-57). 
 
There are total of six distinguishable phases in the pharmaceutical NPD process 
(table 6). Approximately five of every 10,000 compounds tested moves forward 
from the Phase I and II. Furthermore, one of five compounds that moves to clin-
ical trials can successfully complete the Phase III trials.  The first two phases of 
the NPD process typically last about six years. The timeline for potential drug to 
successfully pass the clinical trial phases I to III takes an average of five years, 
which makes the total timeline of the new drug development for more than 10 
years (Pharmaceutical Pricing Policies in a Global Market 2008). 
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Table 6. Phases of the new pharmaceutical product development (Adapted from Pharmaceutical Pricing Policies in a Global 
Market 2008). 
Phase Description 
Drug discovery Researchers in private companies, government and academic research institutions are searching 
promising compounds that are potential for treating diseases. The best compounds are moved fur-
ther to preclinical testing phase. 
Preclinical testing The compounds found in drug discovery phase are further tested in vitro and in vivo in animal 
models. If the specific compounds show promising results, the developer can apply a permission 
from the national marketing authorisation agency to begin human clinical trials. The specifications 
for approval vary in different areas (e.g. United, States and European Union). 
Phase I The first phase of human clinical trials is conducted with relatively small number of healthy vol-
unteers to determine the range of safe dosing and toxicity of the drug compound. 
Phase II In the second phase, the drug compound is tested with a larger group of volunteers, who have 
been diagnosed with the medical condition that the drug is intended to treat. 
Phase III The third phase of the clinical trials includes a larger sample of volunteers, who have been diag-
nosed with the medical condition of interest. The main objective is to demonstrate the efficacy of 
the drug compound and to finalize the dosing. The most likely safety issues are detected in Phase 
III clinical trials, but the subject sample sizes are still too small to detect rare adverse side-effects. 
Marketing authorisation 
application 
After the drug compound have successfully passed the clinical trials, an authorisation to market 
the drug is applied from the authorisation agency. The average time from the application to the 
approval has been 13 to 25 months in the recent years. 
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5. OVERVIEW OF THE CASE COMPANIES 
 
The selected case companies were raw material suppliers for in vitro diagnostics 
(IVD) companies, an IVD company and a pharmaceutical company. All of the 
case companies participate in R&D activities. The group of the case companies 
presents a very homogenous group as they all operate either directly or indirectly 
in very regulated business environment. The size of the companies varied from 
SMEs to large enterprises (LE) based on the European Commission’s definition 
on enterprise size of employees and revenue or balance sheet total (European 
Union recommendation 2003/361). 
 
All the case companies described in this study belongs to the OECD’s “high-tech-
nology industry” category of “pharmaceuticals” and “medical precision, and op-
tical instruments and materials”. In addition, all of the companies are applicable 
either to the “synthesis, and engineering of proteins and peptides” in the proteins 
and other molecules category and “applications in drug delivery and diagnos-
tics” in the nanobiotechnology category of the list-based biotechnology defini-
tion. The companies, results, validation, and conclusions are described as confi-
dential information, and therefore acronyms are used instead of the official com-
pany names. Additionally, the source of information concerning the case compa-
nies the will not be disclosed in the list of reference. However, for the accuracy 
and reliability, only information from case companies’ personnel, official docu-
ments, and website are used. 
 
 
5.1. Case company 1 
 
The case company 1 (CC1) is a raw material supplier for the IVD companies. The 
company is a multinational SME with an annual revenue of approximately 25 
million euros. They have approximately 100 employees and operations in three 
different countries. The company operates on B2B market and the products of 
their customers are also sold in B2B market 
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The questionnaires were sent to four executive level personnel out of whom three 
provided answers. In addition, the results were validated with one of the four 
executives in the CC1. 
 
 
5.2. Case company 2 
 
The case company 2 (CC2) is also a raw material supplier for the IVD companies. 
The company is also a multinational SME with an annual revenue of approxi-
mately 20 million euros. They have total of about 90 employees and operations 
in two countries. The company’s main operations are in B2B market and the 
products of their customer are also sold in B2B market. The CC1 and CC2 oper-
ates in the same business, so the companies can be considered as competitors. 
 
The questionnaires were sent to five executive level personnel out of whom all 
provided answers. In addition, the results were validated with one of the five 
executives in CC2. 
 
 
5.3. Case company 3 
 
The case company 3 (CC3) develops, manufactures, and distributes IVD test an-
alysers and test intended for clinical diagnostics, life science research, food, en-
vironmental, and industrial testing. The CC3 is a Finnish subsidiary of a multi-
national LE, which consolidated annual revenue is approximately 2.26 billion 
USD and the consolidated annual revenue of the diagnostics division is about 
680 million USD. The Finnish subsidiary has a key role in the research and NPD 
of the company group and their annual revenue is about 270 million euros. The 
CC3 has more than 11,200 employees globally and they have operations in more 
than 150 countries. CC1 and CC2 are potential raw material suppliers for CC3. 
The company operates in B2B market and the products of their customer are also 
sold in B2B market as well. 
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The questionnaires were sent to three executive level personnel in Finnish sub-
sidiary from which all of the respondents were able to provide answers. In addi-
tion, the results were validated with one of the three executives in the Finnish 
subsidiary of CC3. 
 
 
5.4. Case company 4 
 
The case company 4 (CC4) is a life science and pharmaceutical company that de-
velops, manufactures, and distributes pharmaceuticals for diseases that for ex-
ample CC3 provides clinical IVD tests for. The CC4 is a Finnish subsidiary of a 
multinational LE, which consolidated annual revenue is approximately 35 billion 
euros. The annual revenue of the Finnish subsidiary is approximately 900 million 
euros and they have a significant role in some of the pharmaceutical develop-
ment and manufacturing in the company group. The CC4 has more than 120,000 
employees globally and they have operations in more than 80 different countries. 
The company operates in B2B market, but the products are supplied to both B2B 
and B2C markets. 
 
The questionnaires were sent to four top-level executives in Finnish subsidiary 
from which three were able to provide answers. In addition, the results were val-
idated with one of the three executives in Finnish subsidiary.  
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6. METHODOLOGY 
 
In this study two questionnaires were used to evaluate the resource allocation for 
innovation and innovation strategy of the case companies: sense and respond 
(S&R) questionnaire and analytical hierarchy process (AHP) questionnaire. The 
S&R-questionnaire was used to analyse how the resource allocations adapts with 
changing business environment and AHP-questionnaire was used to evaluate 
the innovation strategy of the case companies respectively. For both methods 
four main criteria, that were considered to reflect the open and closed innovation 
strategies best, were defined and selected: technology, knowledge, development, 
co-operation criteria. In addition, in the S&R-questionnaire five subattributes 
was used to reflect the four main criteria and quality, cost, time, and flexibility 
criteria respectively (Takala 2002: 345-350). 
 
 
6.1. Definition of the main attributes 
 
6.1.1. Technology 
 
The definition of technology is wide. It can be described as products, tools or 
processes integrated directly into the company’s operations. Technology is used 
to increase productivity and efficiency and to develop better products. In this 
study, the technology criterion included leading-edge technology, external tech-
nology, external product development ideas, external intellectual property, and 
high-quality contract research. The technology criterion and its subattributes 
were corresponding to the quality criterion described by Takala (2002). 
 
Leading-edge technology means the latest technology available for the company. 
External technology means the use of technology developed outside of the com-
pany but integrated into its core processes. External product development ideas 
mean the exploitation of product development ideas arising outside of the com-
pany but developed in-house. External intellectual property means licensing ex-
ternal IPR to be used in the company’s products and/or processes. High-quality 
contract research means the use of high technology and high-quality contract 
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research as a part of the company’s processes. The technology main attribute ad-
dresses the priorities of these external resources for the company in the past and 
the future timeframe to leverage them as inputs as a part of the company’s inno-
vation strategy. 
 
6.1.2. Knowledge 
 
Knowledge is an intangible value of organization which is considered as an asset 
and can be referred as an intellectual capital. Knowledge is based on skills rather 
than physical objects. Knowledge tends to provide a company a competitive ad-
vantage against its competitors. In this study, the knowledge attribute included 
core competence, cost of publications, cost of IP, cost for attending to alternative 
markets, and value of own IP. The knowledge criterion and its subattributes were 
corresponding to the cost criterion described by Takala (2002). 
 
Cost of core competence means the expenses that are caused from the core 
knowledge. Cost of publications means the expenses arising from publishing in-
formation that supports the business. Cost if IP means the explicit expenses of 
the IPR that the company uses in its business. Cost for attending to alternative 
markets means expenses ensuing from attending to markets other than the com-
pany’s main market. Value of own IP means the material and immaterial valua-
tion of the company’s own IP. The knowledge main criterion addresses the pri-
orities of these resources for the company in the past and the future timeframe to 
leverage these knowledge-related inputs as a part of the company’s innovation 
strategy. 
 
6.1.3. Development 
 
Development can be considered as actions of companies to introduce and im-
prove products and procedures from which they seek growth. In this study, the 
development criterion included time used for basic research, control of the com-
pany’s own IP, internal new product development ideas, timing in current mar-
ket and own R&D. The development criterion and its subattributes were corre-
sponding to the time criterion described by Takala (2002). 
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Time used for basic research means the effort that is allocated for the basic re-
search that aims to deeper understanding of concepts in the company. Control of 
own IP means how actively the company controls the use of its own IP by other 
companies and how much time the company uses for this control. The timing in 
current market means the company’s timing in general in its main market com-
pared to the global trends. The own R&D means how much time and effort the 
company puts on its own R&D in general. The development main criterion ad-
dresses the priorities of these resources for the company in the past and the future 
timeframe to leverage these internal inputs as a part of the company’s innovation 
strategy. 
 
6.1.4. Co-operation 
 
Co-operation is a process where two entities or more are working together to-
wards mutual economic benefit. In this study, the co-operation criterion included 
business model management, venture management, outsourcing management, 
involvement in other markets, and collaboration management. The co-operation 
criterion and its subattributes were corresponding to the flexibility criterion de-
scribed by Takala (2002). 
 
Business model management means the responses of core aspects of business to 
the corporate strategy and competitive advantage. Venture management means 
the activity of which the company pursuits different ventures, e.g. M&As, joint 
ventures, or strategic alliances. Outsourcing management means the activity of 
the company towards outsourcing its projects and processes. Involvement in 
other markets means the activity of the company in other markets than its main 
market. Collaboration management means the activity of the company to pursuit 
collaboration with other parties, e.g. academic, institutional, or industrial part-
ners. The co-operation main criterion addresses the priorities of these resources 
for the company in the past and the future timeframe to leverage these collabo-
ration inputs as a part of the company’s innovation strategy. 
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6.2. Sense and respond 
 
S&R method is an instrument that can be utilised for recognition, expectation, 
adaption, and responding to constantly changing business environments and sit-
uations in order to maintain the SCA. The objective of this method is to evaluate 
the resource allocation in companies and to recognize the impaired, balanced, 
and over resourced assets. 
 
The S&R-questionnaire used in this study contained questions regarding the at-
tributes that was considered as critical factors and has an influence on the re-
source allocation of the innovation strategy in the case companies. The question-
naire form included quantitative estimations of each attribute in scale 1-10, where 
the 1 represented low and 10 represented high values respectively. Total of 3-5 
management executives were asked to fill the S&R-questionnaire, after which the 
results were analysed in order to determine the critical factors in the case compa-
nies’ innovation strategy. 
 
The S&R questionnaire were comprised of questions concerning the main attrib-
utes and total of 20 subattribute questions derived from the main attributes. The 
main and subattribute questions were evaluated based on empirical experience 
of the respondent in terms of whether the performance of an attribute has im-
proved, stayed the same, or declined in the past 3-5 years. Additionally, the same 
evaluation was done based on the expectations of the respondents that do they 
believe that the performance of an attribute will improve, stay the same, or de-
cline in the next 3-5 years. Each of the attributes was also evaluated against the 
case company’s competitors based on subjective estimation of the respondents, 
whether the case company’s performance was better, same, or worse compared 
to its competitors. The S&R-questionnaire used in this study is described in Ap-
pendix 2. 
 
The relative performance of a case company compared to its competitors was 
determined a relative weight of the worse, same, and better answers based on the 
answers of the respondents (equation 1). The best fitting subjective performance 
was chosen based on the highest value 
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!"#$%&'"	)"*+,*-$./" = ∑234564789:3;∑234564789:3<=∑234564789:3>=∑23456789:3? (1) 
 
In the equation the Performancei represents the sum of worse, same, or better an-
swers of the respondents, PerformanceW represents the sum of the “worse” an-
swers of the respondents, PerformanceS represents the sum of the “same” answers 
of the respondents, and PerformanceB represents the sum of the “better” answers 
of the respondents.	
 
6.2.1. Resource allocation index 
 
Critical factor index (CFI) is a strategy instrument that supports strategy deci-
sions that are based on empirical expectations and experiences. The combination 
of standard deviation (SD) of experiences and expectations leads to measurement 
of CFI. Compared to CFI, the balanced critical factor index (BCFI) provides more 
reliable indication of critical factors and therefore offers an extensive analysis tool 
as well (Nadler & Takala 2009: 1333-1339). In the BCFI the critical and non-critical 
attributes are more easily recognized, in order to better define the strategy and 
adjust different resources according to it. 
 
An enhanced model called scaled critical factor index (SCFI) has also been devel-
oped to better reflect the core theory of S&R (Liu, Wu, Zhao & Takala 2011: 1010-
1015). The even more improved model of SCFI is called normalized scaled critical 
factor index (NSCFI). The difference between SCFI and NSCFI models is the gap 
index and development index, which are formulated into the NSCFI model with 
an exponential function to keep the range of data in moderate level. In the CFI, 
BCFI, and SCFI models, the gap index may cause huge variation in small sample 
volumes and lead to exaggerated interpretation because of the multiplication by 
0.1 or 10 (Liu & Liang 2015: 1019-1037). For the CFI, BCFI, SCFI, and NSCFI, the 
Performance index, Importance index, Gap index or Gap index’, Development 
index or Development index’, and SD indexes for expectation and experience 
(equations 2-9) are calculated before the final analysis (Liu & Liang 2015; Liu et 
al 2011): 
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@"*+,*-$./"	&.A"B = CD348E3(3GH34I39:3)KL  (2) 
 
M-),*%$./"	&.A"B = CD348E3(3GH3:N8NI69)KL  (3) 
 
O$)	&.A"B = PCD348E3(3GH34I39:3)QCD348E3(3GH3:N8NI69)KL − 1P (4) 
 
O$)	&.A"BT = 2VWXYZ[X(X\]X^_Z_;`a)bVWXYZ[X(X\]XY;Xa^X)cd  (5) 
 
e"'"#,)-".%	&.A"B = |(g"%%"*% − i,*j"%)	× 	0.9 − 1| (6) 
 
e"'"#,)-".%	&.A"BT = 2(o64p3%Qq3NN34%) (7) 
 
re3GH3:N8NI69	&.A"B = stX\]X^_Z_;`aKL + 1 (8) 
 
re3GH34I39:3 	&.A"B = stX\]XY;Xa^XKL + 1 (9) 
 
The Gap indexes distinguish the gap between experiences and expectations of a 
particular attribute and helps to understand whether the expectations are corre-
sponding to the reality. The Development indexes indicates the direction of the 
attributes’ performance. Importance index evaluates the importance of specific 
attribute among other attributes, as it reflects the expectations of respondent con-
cerning the attribute. Performance index on the other hand, evaluates the actual 
performance concerning specific attribute based on the empirical experience of 
the respondents. SD indexes for expectation and experience measures the re-
spondent’s similarity or controversy of an attribute based on the expectation and 
experience they might have. Using these indexes, the CFI, BCFI, SCFI, and NSCFI 
models can be calculated by using equations 10-13 (Liu & Liang 2015; Liu et al 
2011): 
 
vwM = stX\]XY;Xa^X	×	stX\]X^_Z_;`aI7H64N89:3	I9x3G	×	E8H	I9x3G	×	x3D3y6H739N	I9x3G − 1 (10) 
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zvwM = stX\]X^_Z_;`a	I9x3G	×	stX\]XY;Xa^X	I9x3G	×	H34564789:3	I9x3GI7H64N89:3	I9x3G	×	E8H	I9x3G	×	x3D3y6H739N	I9x3G  (11) 
 
rvwM = {ca∑ |3GH34I39:3(;)}~a;c {ca∑ |3GH34I39:3(;)QKL}~a;c 	×	234564789:3	I9x3GÄ8H	I9x3G	×	t3D3y6H739N	I9x3G	×	Å7H64N89:3	I9x3G  (12) 
 
ÇrvwM = {ca∑ |3GH34I39:3(;)}~a;c {ca∑ |3GH3:N8NI69(;)QKK}~a;c 	×	234564789:3	I9x3GÄ8H	I9x3GÉ	×	t3D3y6H739N	I9x3GÉ	×	Å7H64N89:3	I9x3GÉ  (13) 
 
In the equations, the n represents the number of respondents. 
 
From each model, the resource allocation indexes (RAI) were calculated and the 
results from the models using relative subattribute values were presented in 
graphical form and compared to each other. The relative critical factor values 
were determined by dividing an individual value with the sum of corresponding 
critical factor model values (Liu et al 2011). The average resource level was de-
termined as a multiplicative inverse number of the subattributes (equation 14). 
One-third deviation around the average resource level was used as an upper and 
lower limit values. The specific subattribute was considered to be in balance if 
the subattribute value was between the range of one-third deviations of the av-
erage resource level. Accordingly, the subattribute was considered to be under 
resourced if the value of the subattribute was lower than one-third deviation of 
the average resource level, and over resourced if the value of the subattribute 
was over than one-third deviation of the average resource level respectively.  
 
Ñ'"*$Ö"	*"j,Ü*/"	#"'"# = K9á7q34	65	páqq8NN4IqáN3p	 (14) 
 
The trend of the subattributes inquired in the S&R-questionnaire was determined 
by comparing the past and the future values of each subattributes. The trend 
shows how the subattributes changes between the past and the future timeframe. 
If both the past and the future timeframe values of a subattribute was in the range 
of one-third deviation of average resource level, there were considered to be no 
change in the trend of a subattribute and the trend was labelled as the “same”. 
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The trend was considered to be “worse”, if the values changed from balanced to 
under or over resourced. Accordingly, the trend was considered to be “better”, if 
the values changed from under or over resourced to balanced subattribute. If 
both the past and the future timeframe values of a subattribute were under or 
over resourced, but the future timeframe values of the subattribute was moving 
towards or further to the balanced resource-level, the trend was also considered 
to be “better” or “worse” respectively (Liu et al 2011). 
 
 
6.3. Analytical hierarchy process 
 
AHP method was created by Thomas L. Saaty as a multi-objective, and multi-
criterion decision-making tool that helps to evaluate different attributes pairwise. 
The method provides a framework for problem solving by breaking down the 
problem and prioritizes them to in each hierarchy (Saaty 1984: 285-286). The 
method enables to evaluate alternative elements together and makes them com-
parable in a quantitative way (Toshev & Takala 2010: 14-18). It has been used in 
a variety of problems in different industries as a decision-making tool among 
both managers and researchers. It takes priorities of different alternatives into 
consideration and weights them based on their level of importance. The aim of 
the method is to find the best solution available for each problem (Saaty 1980: 4). 
 
The AHP method also gives concrete results for rational decision-making process 
and enables its users to tackle complex issues by laying them in hierarchical 
structure. The scale used in AHP-process range between 1 to 9 for least important 
to absolute value, with 1 meaning that both of the criteria are equally important. 
The relative score for each attribute is determined by taking into account all the 
relevant criteria and their pairwise comparisons, so that all of the elements and 
alternatives are evaluated in the lowest level as well (a. Takala, Hirvelä, Liu & 
Malindžák 2007: 326-344). 
 
The AHP-questionnaire used in this study consisted of subjective evaluation of 
priority weights on how the main attributes mentioned in chapter 6.1 have been 
divided in the case companies for the past 3-5 years based on the empirical 
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6.3.1. Innovation strategy index 
 
The analytical model for innovation strategy was also used to calculate the inno-
vation strategy index (ISI) of the case companies in four different groups using 
the technology, knowledge, development, and co-operation attributes. The ISI 
takes into account the four main criteria, which are evaluated with the AHP 
method. The ISI can be presented with the equation 16 (a. Takala et al 2007). 
 
MrM = +ÅsÅ(ã, ç, e, v) (16) 
 
Where the T represents technology, K represents knowledge, D represents devel-
opment, and C represents co-operation. 
 
The normalized weights of the main attributes in ISI-model are calculated with 
the equations 17-20 (Liu 2013: 2821-2814). The normalized values are used in or-
der to emphasize the value for Co-operation, as according to the equations the 
sum of T’, K’, and D´ is 1. This concludes that the sum of T’, K’, D’, and C’ is < 1. 
 
ãT = éé=è=t (17) 
 
çT = èé=è=t (18) 
 
eT = té=è=t (19) 
 
vT = êé=è=t=ê (20) 
 
In the equations above the T represents technology, K represents knowledge, D 
represents development, and C represents co-operation.	
 
The innovation strategies evaluated in this study were inside-out open innova-
tion strategy, outside-in open innovation strategy, closed innovation strategy, 
and coupled open innovation strategy. The method was originally developed for 
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detection of preferable operations strategy type (b. Takala, Kamdee, Hirvelä & 
Kyllönen 2007: 110-112). The results derived from AHP method were applied to 
identify the innovation strategy type of the case companies. Furthermore, the 
equations 21-24, that represent analytical models for ISI, were used to determine 
the innovation strategy for each case company. 
 
Më = ∅~1 − î1 − ã%cïñ (1 − 0.9 × e%)(1 − 0.9 × ç%) × v%cï (21) 
 
ëM = ó~1 − 1(1 − v%)|Ñzr[(0.95 × ã%− 0.285) × (0.95 × e%− 0,285) ×
(0.95 × ç%− 0.285)]}ú (22) 
 
vM = ù~1 − î1 − ç%cïñ (1 − 0.9 × e%)(1 − 0.9 × ã%) × v%cï (23) 
 
v, = Kû (M.j&A" − ,Ü% + v#,j"A	&..,'$%&,.) (24) 
 
In the equations above the IO represents inside-out OI strategy, the OI outside-
in OI strategy, the CI closed innovation strategy, and the Co coupled OI strategy 
respectively. The T represents technology, D development, K knowledge, and C 
co-operation attributes respectively. 
 
The equations 21-24 are modified from manufacturing strategy index developed 
by Takala et al (2007 b.). These analytical models have been used globally in more 
than 100 case company studies (Liu & Takala 2009: 1-19). The same equations are 
also applied to calculate the innovation strategies of RAI in each critical factor 
group using weighted values of technology, knowledge, development, and co-
operation derived from S&R method. 
 
 
6.4. Responsiveness, agility, and leanness -model 
 
The responsiveness, agility, and leanness (RAL) -model supports the theory of 
analytical models that uses four main attributes, e.g. technology, knowledge, 
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development, and flexibility. Originally the RAL-model has been created to eval-
uate success factors in logistics operations, but it can be used in all operations 
and manufacturing strategies as well. The RAL -model has been validated and 
used in companies of all sizes from different industries (Si, Takala, Liu, Toshev, 
& Tang 2008: 1915-1919). The model has been later modified by Takala (2002) by 
taking product and production perspective into consideration. 
 
The RAL-model is based on the equilateral shape triangle that reviews the inno-
vation strategy. The triangle is formed by the normalized weights of the main 
attributes either by RAI or AHP methods. The sides of the triangle represent the 
values for responsiveness, agility, and leanness. The responsiveness is consid-
ered as the “speed by which the system satisfies unanticipated requirements”, 
the agility is considered as the “speed by which the system adapts optimal cost 
structure”, and the leanness “minimizes waste in all resources and activities” (b. 
Takala et al 2007). 
 
The shape of the triangle is determined by the lengths of the sides and the angles 
formed by the corners of the sides. These values enable to form a diagram that 
indicates the innovation strategy and the competitive group of the case compa-
nies (figure 15A). The triangle will always be symmetric when all the variables 
of technology, knowledge, development, and co-operation are 1. In this case the 
sides, responsiveness, agility, and leanness, are equal and the triangle can be de-
fined by using a unit circle drawn outside the RAL-triangle (figure 14B). The ra-
dius of the outside circle represents the values of the innovation strategies. Ac-
cordingly, the inner circle helps to determine the angle between the innovation 
strategy line segments. 
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(RMSE), and maximum absolute deviation (MAD) were used to determine the 
risk level of the innovation strategy by the SCA. The MAPE, RMSE, and MAD 
was determined by equations 26-28 (Tasmin, Takala, Bakr, Shylina, Nizialek & 
Che Rusuli 2016: 73-85).  
 
£Ñ@§ = rvÑ = 1 − ∑ P•sQ•ä•s P¶,ß,®  (26) 
 
!£r§ = rvÑ = 1 − {∑ î•sQ•ä•s ñû¶,ß,®  (27) 
 
£Ñe = rvÑ = 1 −-$B¶,ß,® P•sQ•ä•s P (28) 
 
In the equations, the BS represents the inside-out, outside-in, and closed innova-
tion triangle angle values in the ISI model and the BR represents the inside-out, 
outside-in, and closed innovation triangle angle values in the RAI model. The 
SCA values of the MAPE, RMSE, and MAD relates to the amount of how the 
resource allocation supports the companies’ innovation strategy. The closer the 
SCA values are to 1, the more consistent the resource allocation and innovation 
strategy are (a. Takala, Koskinen, Liu, TAS & Muhos 2013: 45-54). 
 
 
6.6. Weak market test 
 
For a new model constructs, three market tests have been proposed. The first one 
is the weak market test (WMT), which means a person responsible in a case com-
pany is willing to use the constructed model. The second test is called semi-
strong market test (S-SMT), which means that the constructed model is widely 
accepted by the case companies. The third test is called the strong market test 
(SMT), and it means that the new constructed model is systematically used in the 
case companies to produce competitive results compared to its counterparts 
(Kasanen, Lukka & Siitonen 1993: 241-264). As this study is the first attempt to 
quantitatively model the innovation strategy of the case companies with these 
models, it aims to satisfy the WMT and also pave the way for the future market 
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tests that are defined by the constructive research approach (CRA). The WMT 
proposes that the constructed model has business interest even though it does 
not indicate that this new constructed model will bring any direct economic ben-
efits to the case companies (Kasanen et al 1993). To pass the WMT it is enough 
that the case company has adopted the CRA (Lindholm 2008: 343-358). 
 
In this study the WMT was tested in all four case companies, which helps to gen-
eralize these results on a wider scale of customers. The WMT was also used to 
validate both the RAI and the ISI results derived from the S&R- and AHP-ques-
tionnaires. During the WMT, all of the obtained results were presented to the 
case companies executive without any analysis of the company’s innovation 
strategy. It was also asked how the determined results meets the reality, and 
what actually has been the company’s innovation strategy during the past 3-5 
years of period and according to the company’s strategy, what it will be for the 
next 3-5 years of period. The case companies were also asked to give reasons why 
they think the company has and will pursue for the certain innovation strategy 
in order to be sure that respondents in the WMT has understood the categoriza-
tion of different innovation strategies. 
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7. RESULTS 
 
This chapter describes the results of the case companies that was analysed in the 
study. The information presented in this chapter is confidential, and therefore 
acronyms are used instead of the official company names. The source of the in-
formation is not disclosed in the text nor the list of reference. 
 
 
7.1. Case company 1 
 
7.1.1. Resource allocation index 
 
The fluctuation of the resource allocation model values was highest in the CFI 
and BCFI models, and moderate in the SCFI model. In general, the values were 
higher in these models compared to the NSCFI model. The deviation between 
the past and the future values were high in the BCFI model and low in the SCFI 
and the NSCFI models, although the SCFI model did stress more the minor dif-
ferences in the answers than the NSCFI model (figure 17). 
 
 
Figure 17. Resource allocation model results of CC1. The results for each subat-
tribute from left to right are P-CFI, F-CFI, P- BCFI, F-BCFI, P-SCFI, F-SCFI, P-
NSCFI, and F-NSCFI. Red indicates that the subattribute is under resourced, 
yellow indicates that it is over resourced, and green indicates that it is in bal-
ance. 
 
Because the SD was 0 in the CFI model numerator, both the past and the future 
values in the “C4: expertise in other markets” attribute were 0 as well. The future 
values of the “C5: collaboration management” attribute was more than 3 times of 
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the upper limit value. The resource allocation was under resourced in following 
subattributes: “K3: the cost of intellectual property”, “K5: value of own intellec-
tual property”, “D1: time used for basic research”, “D3: internal product devel-
opment ideas”, and “D5: own research & development” in all of the resource 
allocation models. The trend between the past and the future values was shown 
to be better in the subattribute “D3: internal product development ideas” in all 
other resource allocation models except the CFI model. All the trends of the sub-
attributes in the resource allocation models are described in Appendix 4. 
 
The performance compared to competitors were scattered among different main 
attributes (table 8). The knowledge and the development attributes were consid-
ered to perform better compared to competitors by the majority of the respond-
ents. However, the co-operation attribute was considered to perform worse com-
pared to competitors in opinion of all respondents and the answers to the tech-
nology attribute were scattered between the "worse", "same" and "better". 
 
Table 8. The performance comparison to competitors in CC1. The highest val-
ues in different attributes are marked in bold. 
Attributes Worse Same Better 
Technology 0.33 0.33 0.33 
Knowledge 0 0.33 0.67 
Development 0.33 0 0.67 
Co-operation 1.00 0 0 
 
7.1.2. Innovation strategy index 
 
The distribution of the technology, knowledge, development, and co-operation 
in the past timeframe were 0.060, 0.564, 0.375, and 0.045 respectively. The corre-
sponding distribution in the future timeframe were 0.548, 0.158, 0.294, and 0.227 
respectively (figure 18). The corresponding priority weight values for the same 
main attributes in the past timeframe were 0.167, 0.444, 0.389, and 0.100 and for 
the future timeframe 0.400, 0.267, 0.333, and 0.250 respectively. 
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Table 9. Innovation strategy results of different models in CC1. The highest val-
ues in each are marked in bold. 
PAST TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9293 0.8473 0.9612 0.9454 
Priority weight 0.9186 0.8977 0.9393 0.9289 
CFI 0.8975 0.9252 0.7567 0.8271 
BCFI 0.9147 0.9914 0.9075 0.9111 
SCFI 0.9103 0.9844 0.8972 0.9037 
NSCFI 0.9099 0.9901 0.9023 0.9061 
FUTURE TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9301 0.9564 0.8955 0.9128 
Priority weight 0.9118 0.9657 0.8994 0.9056 
CFI 0.9152 0.8717 0.8574 0.8863 
BCFI 0.8850 0.8788 0.9233 0.9041 
SCFI 0.8755 0.8961 0.9136 0.8946 
NSCFI 0.9022 0.9741 0.9087 0.9055 
 
7.1.4. Sustainable competitive advantage 
 
In the past timeframe the highest SCA values was achieved with BCFI model and 
in the future timeframe with NSCFI model respectively (table 10). The highest 
values in the past timeframe were 0.7888 in MAPE, 0.8698 in RMSE, and 0.8993 
in MAD. The highest values in the future timeframe were 0.9482 in MAPE, 0.9682 
in RMSE, and 0.9741 in MAD respectively. 
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Table 10. Sustainable competitive advantage values in CC1. The highest values 
in each model are marked in bold. 
PAST TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.7077 0.8064 0.8472 
BCFI 0.7888 0.8699 0.8993 
SCFI 0.7876 0.8683 0.8988 
NSCFI 0.7844 0.8672 0.8972 
FUTURE TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.9299 0.9539 0.9644 
BCFI 0.8927 0.9314 0.9476 
SCFI 0.9094 0.9448 0.9557 
NSCFI 0.9482 0.9682 0.9741 
 
 
7.2. Case company 2 
 
7.2.1. Resource allocation index 
 
There were some fluctuations in the resource allocation model values with iso-
lated subattributes in case of CFI, BCFI, and SCFI models. In these models the 
future values for the “T2: use of external technology” -attribute was almost 3 
times of the upper limit value (figure 21). In other attributes the variation be-
tween past and the future values were moderate. In general, the fluctuation was 
lowest in the NSCFI model. The resource allocation was under resourced in the 
subattributes “K2: cost of publications“, and “D1: time used for basic research“ 
in every other resource allocation model, expect the CFI model. In the CFI model 
the “cost of publications” was over resourced in both the past and the future 
timeframe with the trend getting closer to balanced, and the “time used for basic 
researched” was balanced in both the past and the future timeframe with the 
trend remaining same. The trend between the past and the future values was 
shown to be better in the subattribute “T2: use of external technology” in all of 
the resource allocation models. In addition, the trend for subattribute “D5: own 
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research & development” was shown to be better in every other resource alloca-
tion model, except the CFI model. All the trends of the subattributes in the re-
source allocation models are described in Appendix 5. 
 
 
Figure 21. Resource allocation model results of CC2. The results for each subat-
tribute from left to right are P-CFI, F-CFI, P- BCFI, F-BCFI, P-SCFI, F-SCFI, P-
NSCFI, and F-NSCFI. Red indicates that the subattribute is under resourced, 
yellow indicates that it is over resourced, and green indicates that it is in bal-
ance. 
 
The performance compared to competitors were evaluated to be the same among 
the different main attributes (table 11). However, the development attribute was 
considered to perform either worse or the same as compared to competitors 
based on the opinion of the respondents. 
 
Table 11. The performance comparison to competitors in CC2. The highest val-
ues in different attributes are marked in bold. 
Attributes Worse Same Better 
Technology 0 0.60 0.40 
Knowledge 0 0.80 0.2 
Development 0.40 0.40 0.20 
Co-operation 0 0.80 0.20 
 
7.2.2. Innovation strategy index 
 
The distribution for the technology, knowledge, development, and co-operation 
in the past timeframe were 0.119, 0.180, 0.701, and 0.262 respectively. The corre-
sponding distribution in the future timeframe were 0.555, 0.282, 0.163, and 0.553 
respectively (figure 22). The ICR for the past timeframe was 0.115 and for the 
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future timeframe 0.060. The priority weights for the corresponding main attrib-
utes were 0.313, 0.188, 0.500, and 0.200 in the past timeframe and 0.357, 0.214, 
0.429, and 0.300 in the future timeframe respectively. 
 
 
Figure 22. The main attribute distributions in the CC2. 
 
The main attribute ISI model values correlated moderately with the priority 
weight values in both the past and the future timeframe (figure 22). The SD for 
the main attributes in the past scenario varied between 0.005 to 0.142 and be-
tween 0.048 to 0.188 in the future timeframe. 
 
7.2.3. Responsiveness agility, and leanness -model comparison 
 
The main attribute ISI model results of the past timeframe did not correlate in the 
RAL -model with the priority weight values derived from the AHP-question-
naire. However, the results did correlate in the future timeframe (figure 23). In 
the past timeframe the highest value in the innovation strategy was in the closed 
innovation strategy based on the ISI model and in the outside-in OI strategy 
based on the priority weight model. In the future timeframe the highest values 
in the innovation strategy were in the outside-in OI strategy both in the ISI and 
the priority weight models. 
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out > Coupled > Closed innovation in the priority weight model (table 12). The 
NSCFI model did correlate with ISI model in the past timeframe. In the future 
timeframe the order of the innovation strategy models was the same in the ISI 
and the priority weight models: outside-in > inside-out > Coupled > Closed in-
novation. 
 
Table 12. Innovation strategy results of different models in CC2. The highest 
values in each are marked in bold. 
PAST TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.8994 0.8560 0.9082 0.9038 
Priority weight 0.9141 0.9502 0.9011 0.9076 
CFI 0.9206 0.9473 0.9111 0.9159 
BCFI 0.9248 0.9352 0.9420 0.9334 
SCFI 0.9078 0.9108 0.9517 0.9297 
NSCFI 0.8997 0.8960 0.9380 0.9189 
FUTURE TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9068 0.9636 0.8793 0.8930 
Priority weight 0.9036 0.9430 0.8879 0.8958 
CFI 0.9188 0.9609 0.8703 0.8945 
BCFI 0.9086 0.9654 0.8966 0.9026 
SCFI 0.8701 0.9634 0.9073 0.8887 
NSCFI 0.8817 0.9287 0.9150 0.8983 
 
7.2.4. Sustainable competitive advantage 
 
In the past timeframe the highest SCA values was achieved with the NSCFI 
model and in the future timeframe with BCFI model respectively (table 13). The 
highest values in the past timeframe were 0.9575 in MAPE, 0.9728 in RMSE, and 
0.9784 in MAD. The highest values in the future timeframe were 0.9807 in MAPE, 
0.9883 in RMSE, and 0.9906 in MAD respectively. 
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Table 13. Sustainable competitive advantage values in CC2. The highest values 
in each model are marked in bold. 
PAST TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.9035 0.9401 0.9529 
BCFI 0.9384 0.9622 0.9699 
SCFI 0.9503 0.9683 0.9748 
NSCFI 0.9575 0.9728 0.9784 
FUTURE TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.9786 0.9862 0.9892 
BCFI 0.9807 0.9883 0.9906 
SCFI 0.9384 0.9582 0.9689 
NSCFI 0.9207 0.9515 0.9614 
 
 
7.3. Case company 3 
 
7.3.1. Resource allocation index 
 
There were some fluctuations in the resource allocation values with isolated sub-
attributes in case of CFI, BCFI, and SCFI models. In these models, the past values 
for the “D3: internal product development ideas” was more than 2 times of the 
determined upper limit value (figure 25). In other subattributes the fluctuations 
were high only in some specific cases. In general, the fluctuation was lowest in 
the NSCFI model. The resource allocation was under resourced in the subattrib-
utes “D1: time used for basic research” and “D2: control of own intellectual prop-
erty” in all of the resource allocation models. Accordingly, the trend between the 
past and the future timeframe was shown to be better in the subattributes “D3: 
internal product development ideas” and “C1: business model management” in 
all of the resource allocation models. All the trends of the subattributes in the 
resource allocation models are described in Appendix 6. 
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Figure 25. Resource allocation model results of CC3. The results for each subat-
tribute from left to right are P-CFI, F-CFI, P-BCFI, F-BCFI, P-SCFI, F-SCFI, P-
NSCFI, and F-NSCFI. Red indicates that the subattribute is under resourced, 
yellow indicates that it is over resourced, and green indicates that it is in bal-
ance. 
 
The performance compared to competitors were evaluated to be the same among 
most of the attributes (table 14). However, the knowledge attribute values were 
scattered between the worse, same, and better values. 
 
Table 14. The performance comparison to competitors in CC3. The highest val-
ues in different attributes are marked in bold. 
Attributes Worse Same Better 
Technology 0.33 0.67 0 
Knowledge 0.33 0.33 0.33 
Development 0 0.67 0.33 
Co-operation 0.00 0.67 0.33 
 
7.3.2. Innovation strategy index 
 
The distribution for the technology, knowledge, development, and co-operation 
in the past timeframe were 0.491, 0.152, 0.357, and 0.108 respectively. The corre-
sponding distribution in the future timeframe were 0.606, 0.128, 0.267, and 0.061 
respectively (figure 26). The ICR for the past timeframe was 0.156 and for the 
future timeframe 0.111. The priority weight for the corresponding main attrib-
utes were 0.444, 0.222, 0.333, and 0.100 in the past timeframe and 0.500, 0.250, 
0.250, and 0.200 in the future timeframe respectively. 
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Figure 26. The main attribute distribution in the CC3. 
 
The main attribute ISI model values correlated well with the priority weight val-
ues in both the past and the future timeframe (figure 26). The SD for the main 
attributes in the past timeframe varied between 0.006 to 0.049 and between 0.012 
to 0.098 in the future timeframe. 
 
7.3.3. Responsiveness agility, and leanness -model comparison 
 
The main attribute ISI model results of the past timeframe did correlate moder-
ately in the RAL-model with the priority weight values derived from the AHP-
questionnaire. However, the results did not correlate in the future timeframe (fig-
ure 27).  In the past timeframe the highest value in the innovation strategy was 
in the inside-out OI strategy based on both the ISI model and priority weight 
model. In the future timeframe the highest values in the innovation strategy were 
in the inside-out OI strategy in the ISI model and outside-in OI strategy in the 
priority weight model respectively. 
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The order of the innovation strategy types in the future timeframe ISI model was 
the same as in the past timeframe. 
 
Table 15. Innovation strategy results of different models in CC3. The highest 
values in each model are marked in bold. 
PAST TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9411 0.9010 0.9159 0.9285 
Priority weight 0.9384 0.9384 0.9231 0.9308 
CFI 0.9576 0.8404 0.9561 0.9568 
BCFI 0.9523 0.9109 0.9503 0.9513 
SCFI 0.9380 0.9027 0.9393 0.9386 
NSCFI 0.9288 0.9471 0.9295 0.9291 
FUTURE TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9592 0.8923 0.9324 0.9458 
Priority weight 0.9275 0.9397 0.9078 0.9176 
CFI 0.8955 0.9379 0.8920 0.8937 
BCFI 0.8826 0.9904 0.8783 0.8804 
SCFI 0.8685 0.9882 0.8711 0.8698 
NSCFI 0.8966 0.9912 0.8975 0.8970 
 
7.3.4. Sustainable competitive advantage 
 
In the past timeframe the highest SCA values was achieved with the BCFI model 
and in the future timeframe with CFI model respectively (table 16). The highest 
values in the past timeframe were 0.9719 in MAPE, 0.9228 in RMSE, and 0.9860 
in MAD. The highest values in the future timeframe were 0.8834 in MAPE, 0.9276 
RMSE, and 0.9432 in MAD respectively. 
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Table 16. Sustainable competitive advantage values in CC3. The highest values 
in each model are marked in bold. 
PAST TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.8908 0.9318 0.9460 
BCFI 0.9719 0.9828 0.9860 
SCFI 0.9713 0.9822 0.9857 
NSCFI 0.9458 0.9631 0.9734 
FUTURE TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.8834 0.9276 0.9432 
BCFI 0.8075 0.8821 0.9061 
SCFI 0.7966 0.8749 0.9009 
NSCFI 0.8269 0.8933 0.9157 
 
 
7.4. Case company 4 
 
7.4.1. Resource allocation index 
 
There were some fluctuations in the resource allocation values with isolated sub-
attributes in case of CFI, BCFI, and SCFI models. In these models, the future val-
ues for the “D3: internal product development ideas” was almost 2.5 times of the 
determined upper limit value (figure 29). In other subattributes the fluctuations 
were high only in some specific cases. In general, the fluctuation was lowest in 
the NSCFI model. The resource allocation was under resourced in the subattrib-
utes “K2: cost of publications” and “D1: time used for basic research” in all of the 
resource allocation models. The trend between the past and the future timeframe 
was shown to be better in the subattributes “T5: use of high-quality contract re-
search” and “K1: cost of core competence” in the NSCFI model. All the trends of 
the subattributes in the resource allocation models are described in Appendix 7. 
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Figure 29. Resource allocation model results of CC4. The results for each subat-
tribute from left to right are P-CFI, F-CFI, P- BCFI, F-BCFI, P-SCFI, F-SCFI, P-
NSCFI, and F-NSCFI. Red indicates that the subattribute is under resourced, 
yellow indicates that it is over resourced, and green indicates that it is in bal-
ance. 
 
The performance compared to competitors were evaluated to be the same among 
most of the attributes (table 17). Only the performance of the knowledge attribute 
values was evaluated to be better. 
 
Table 17. The performance comparison to competitors in CC4. The highest val-
ues in different attributes are marked in bold. 
Attributes Worse Same Better 
Technology 0 1.00 0 
Knowledge 0 0.33 0.67 
Development 0 0.67 0.33 
Co-operation 0.33 0.67 0 
 
7.4.2. Innovation strategy index 
 
The distribution for the technology, knowledge, development, and co-operation 
in the past timeframe were 0.061, 0.356, 0.584, and 0.210 respectively. Accord-
ingly, the distribution in in the future timeframe were 0.620, 0.284, 0.095, and 
0.089 respectively (figure 30). The ICR for the past timeframe was 0.419 and for 
the future timeframe 0.030. The priority weight for the main attributes were 
0.267, 0.200, 0.533, and 0.250 for the past timeframe, and 0.438, 0.250, 0.313, and 
0.200 for the future timeframe respectively. 
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Table 18. Innovation strategy results of different models in CC4. The highest 
values in each model are marked in bold. 
PAST TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.8836 0.8831 0.9222 0.9029 
Priority weight 0.9043 0.9345 0.8966 0.9005 
CFI 0.8922 0.8880 0.9049 0.8985 
BCFI 0.9015 0.8993 0.9295 0.9155 
SCFI 0.9042 0.9738 0.9236 0.9139 
NSCFI 0.9038 0.9554 0.9220 0.9129 
FUTURE TIMEFRAME 
 Inside-out Outside-in Closed 
innovation 
Coupled 
ISI 0.9553 0.9127 0.9383 0.9468 
Priority weight 0.9215 0.9665 0.9057 0.9136 
CFI 0.9135 0.9636 0.9051 0.9093 
BCFI 0.9324 0.9153 0.9396 0.9360 
SCFI 0.9391 0.8762 0.9356 0.9374 
NSCFI 0.9093 0.9821 0.9078 0.9085 
 
7.4.4. Sustainable competitive advantage 
 
The highest SCA values was achieved with the BCFI model in both the past and 
the future timeframe (table 19). The highest values in the past timeframe were 
0.9875 in MAPE, 0.9228 in RMSE, and 0.9860 in MAD. The highest values in the 
future timeframe were 0.9707 in MAPE, 0.9820 in RMSE, and 0.9852 in MAD re-
spectively. 
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Table 19. Sustainable competitive advantage values in CC4. The highest values 
in each model are marked in bold. 
PAST TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.9704 0.9816 0.9850 
BCFI 0.9875 0.9922 0.9936 
SCFI 0.9057 0.9410 0.9534 
NSCFI 0.9254 0.9524 0.9632 
FUTURE TIMEFRAME 
 MAPE RMSE MAD 
CFI 0.8961 0.9365 0.9489 
BCFI 0.9707 0.9820 0.9852 
SCFI 0.9662 0.9778 0.9833 
NSCFI 0.8743 0.9228 0.9382 
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8. ANALYSIS 
 
This chapter analyse in depth the resource allocation and ISI results from the case 
companies used in this study. The results from each case company is validated 
by comparing the results to the WMT results obtained by interviewing the re-
spondents. The name and information presented by the respondents are treated 
as confidential information and therefore they are not disclosed in this chapter. 
nor the list of reference. 
 
 
8.1. Case company 1 
 
8.1.1. Resource allocation 
 
From the resource allocation point-of-view, the NSCFI model is the best model 
for innovation resource allocation analysis in small sample volumes. In this 
model the deviation of the answers between respondents has only a minor affect 
to the individual resource factor values (figure 33). The comparison among the 
past and the future timeframe SCA shows that the resource allocation follows the 
ISI model better in the future timeframe than in the past timeframe. 
 
 
Figure 33. Normalized scaled critical factor index results of CC1. Red indicates 
that the subattribute is under resourced, yellow indicates that it is over re-
sourced, and green indicates that it is in balance. 
 
In the past timeframe all the values in different SCA models were below 0.79 and 
therefore not considered to be high. In the future timeframe most of the SCA 
model values were above 0.90, which makes the general risk level less than 10 % 
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in all of the future timeframe SCA models. This confirms that the resource allo-
cation in general follows the case company’s future innovation strategy well. 
However, no specific RAI model supports both of the ISI models in both 
timeframes simultaneously. 
 
8.1.2. Innovation strategy 
 
In the ISI model the past timeframe innovation strategy type is closed innovation 
as the individual values for different innovation types are highest in this case and 
significantly above the average value of different innovation types. the future 
timeframe the innovation strategy type is outside-in OI based on the ISI model 
as the individual values for different types are highest in this case as well and 
also above the average values of the innovation types (table 20). 
 
Table 20. Innovation strategy type results of CC1. 
 Past Future 
Inside-out 0.9293 0.9301 
Outside-in 0.8473 0.9564 
Closed innovation 0.9612 0.8955 
Coupled 0.9453 0.9128 
AVG 0.9208 0.9237 
SD 0.0507 0.0260 
CV-% 5.50 % 2.81 % 
Area 1.0804 1.1167 
ICR 0.031 0.004 
 
The SD of the innovation strategy types are above 0.015, which implies that there 
is sufficient variation between the innovation types in the past timeframe. The 
coefficient of variation (CV-%) of 5.50 % further supports this fact. In In the future 
timeframe the SD of the innovation strategy types are also significantly above 
0.015, which stands for the fact that there is sufficient variation between the in-
novation strategy types in this case as well. The CV-% in the case of the future 
timeframe is 2.81 % which is lower than in the past timeframe but still high 
enough to point out that there is one innovation strategy type that stands out 
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on the WMT the past experience and the future expectations are well in line with 
the past and the future timeframe ISI model results. 
 
 
8.2. Case company 2 
 
8.2.1. Resource allocation 
 
for the resource allocation, the NSCFI model is the best model for resource allo-
cation analysis in small sample volumes in CC2 as well. In this model the devia-
tion of the answers between respondents had also only a minor affect to the in-
dividual resource factor values (figure 35). The comparison among the past and 
the future timeframe SCA models shows that the resource allocation for the sub-
attributes follows the ISI successfully in both timeframes.  
 
 
Figure 35. Normalized scaled critical factor index results of CC2. Red indicates 
that the subattribute is under resourced, yellow indicates that it is over re-
sourced, and green indicates that it is in balance. 
 
In both the past and the future timeframe all the SCA values were above 0.90, 
which makes the general risk level less than 10 % in all of the SCA values at both 
timeframes. This supports the fact that the resource allocation follows the case 
company’s innovation strategy very well in both timeframes. However, no spe-
cific RAI model supports both of the ISI models in both timeframes simultane-
ously in the case of CC2 neither. 
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8.2.2. Innovation strategy 
 
In the ISI model the past timeframe innovation strategy type is closed innovation 
as the individual innovation strategy values are highest in this case. However, 
the value for the coupled OI strategy is also relatively high compared to the 
closed innovation strategy value. The value for the closed innovation type is only 
slightly above the average values of the innovation types. In the future timeframe 
the innovation strategy type is outside-in OI strategy based on the ISI model as 
the individual values are highest in this case as well, and significantly above the 
average values of the innovation strategy types (table 21). 
 
Table 21. Innovation strategy type results of CC2. 
 Past Future 
Inside-out 0.8994 0.9068 
Outside-in 0.8560 0.9637 
Closed innovation 0.9082 0.8792 
Coupled 0.9038 0.8930 
AVG 0.8918 0.9107 
SD 0.0242 0.0371 
CV-% 2.71 % 4.07 % 
Area 1.0236 1.0905 
ICR 0.115 0.060 
 
The SD of the innovation strategy types are above 0.015, which implies that there 
is sufficient variation between the innovation types in the past timeframe even 
though the CV-% of 2.71 % is only marginally elevated. In the future timeframe 
the SD of the innovation strategy types are also above 0.015, which supports that 
there is sufficient variation between the innovation strategy types in the future 
timeframe as well. In the future timeframe the CV-% is 4.07 %, which is high 
enough to draw the conclusion that there is only one model that stands out from 
the other innovation types. The ICR values are below 0.30 in the past and the 
future timeframe ISI models in case of CC2 as well. Therefore, it can be concluded 
that the answers in case of the CC2 are also reliable and supports the results to 
be used in the decision-making process (b. Takala et al 2013). The total innovation 
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8.3. Case company 3 
 
8.3.1. Resource allocation 
 
The NSCFI model is the best model for innovation resource allocation analysis in 
CC3 in small sample volumes as in the case of CC1 and CC2 as well. In this case 
the deviation of the answers between different respondents had only a minor 
affect to the individual resource factor values (figure 37). The comparison among 
the past and the future timeframe SCA shows that the resource allocation for the 
subattributes follows the ISI better in the past timeframe than in the future 
timeframe. 
 
 
Figure 37. Normalized scaled critical factor index results of CC3. Red indicates 
that the subattribute is under resourced, yellow indicates that it is over re-
sourced, and green indicates that it is in balance. 
 
In the past timeframe almost all of the SCA values are above 0.90, which converts 
to the general risk level less than 10 % in all of the past timeframe SCA models. 
Accordingly, in the future timeframe majority of the SCA are below 0.90, which 
makes the general risk level more than 10 % in majority of the future timeframe 
SCA models respectively. This implies that there are issues around the case com-
pany’s future innovation strategy. Additionally, no specific RAI model supports 
the future ISI model, which also supports the fact that there might be issues 
around the future innovation strategy in the case company. 
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8.3.2. Innovation strategy 
 
In the ISI model the past timeframe innovation strategy type is inside-out OI 
strategy as the individual innovation strategy values are highest in this case and 
moderately above the average value of different innovation types. In the future 
timeframe the innovation strategy type is inside-out OI strategy, because the 
value of this innovation strategy is the highest and sufficiently above the average 
value of the innovation types (table 22). 
 
Table 22. Innovation strategy type results of CC3. 
 Past Future 
Inside-out 0.9411 0.9592 
Outside-in 0.9010 0.8923 
Closed innovation 0.9159 0.9324 
Coupled 0.9285 0.9458 
AVG 0.9216 0.9324 
SD 0.0172 0.0289 
CV-% 1.86 % 3.10 % 
Area 1.0978 1.1182 
ICR 0.156 0.111 
 
The value for coupled OI strategy seems to be relatively high as well in the past 
timeframe. The SD of all the innovation strategy values was 0.0172, which is only 
slightly above the threshold of 0.015, but points out that there is variation be-
tween the innovation strategy types in the past timeframe. However, the CV-% 
of 1.86 % supports the coupled OI strategy as it implies that the dispersion 
around the values are low. In the future timeframe the SD of the innovation strat-
egy types is even higher than in the past timeframe and significantly above the 
threshold of 0.015. This stands for higher variation between the innovation strat-
egy types than in the case of the past timeframe. The CV-% in the case of the 
future timeframe is 3.10 %, which is also higher than in the past timeframe and 
supports the inside-out OI strategy type even further. The ICR values are also 
below the 0.30 in case of both the past and the future timeframes, from which it 
can be derived that the answers in case of CC3 are also reliable and they support 
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have sold in the past some of their operations, which do not fit into their future 
vision of the business. 
 
As the CC3 operates on wider scale of OI strategy landscape, it is hard to deter-
mine the priority innovation strategy for the company based on the ISI model. 
However, based on WMT the result of the ISI model and pattern of both the past 
and the future RAL -model triangles cannot be excluded either (figure 38). Be-
cause of this, it can be determined based on the WMT that the past experience 
and future expectations are in line with the innovation strategy types in both the 
past and the future timeframe ISI models. 
 
 
8.4. Case company 4 
 
8.4.1. Resource allocation 
 
The NSCFI model is the best model for innovation resource allocation analysis in 
small sample volumes as in the other case companies. The deviation of the an-
swers between different respondents had only minor affect to the individual re-
source factor values (figure 39). The comparison among the past and the future 
timeframe SCA shows that the resource allocation for the subattributes follows 
the ISI better in the past timeframe than in the future timeframe. 
 
 
Figure 39. Normalized scaled critical factor index results of CC4. Red indicates 
that the subattribute is under resourced, yellow indicates that it is over re-
sourced, and green indicates that it is in balance. 
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In the past timeframe all of the SCA values are above 0.90 and the highest one 
almost 1. Therefore, it can be concluded that the general risk is significantly less 
than 10 % in all of the past timeframe SCA models. In the future timeframe the 
SCA values are also good and above the 0.90, which also implies that the risk is 
similarly less than 10 %. Additionally, no specific RAI model supports both of 
the ISI models in both timeframes simultaneously in the case of CC4 neither. 
 
8.4.2. Innovation strategy 
 
In the ISI model the past timeframe innovation strategy type is closed innovation 
strategy as the individual innovation strategy values are highest in this case and 
sufficiently above the average value of different innovation types. In the future 
timeframe the highest value for the innovation strategy type is in the inside-out 
OI strategy, but the closed innovation strategy and coupled innovation strategy 
are relatively high as well and over the average value of the innovation strategies 
(table 23). The SD was 0.0186, which is above the threshold of 0.015, and implies 
that there is sufficient variation between the innovation types in the past 
timeframe. Additionally, the CV-% of 2.08 % also supports that closed innovation 
type comes to prominence from the other innovation types. the SD for the future 
timeframe is 0.0184 and. The CV-% in the future timeframe, however, is 1.96 % 
which supports the coupled innovation strategy type is the most prevalent. 
 
Table 23. Innovation strategy type results of CC4. 
 Past Future 
Inside-out 0.8836 0.9553 
Outside-in 0.8831 0.9127 
Closed innovation 0.9222 0.9383 
Coupled 0.9029 0.9468 
AVG 0.8980 0.9382 
SD 0.0186 0.0184 
CV-% 2.08 % 1.96 % 
Area 1.0434 1.1364 
ICR 0.419 0.030 
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9. DISCUSSION 
 
From the four resource allocation models, the NSCFI model seems to work the 
best in resource allocation purposes because it has the lowest fluctuation due to 
the minor differences in the answers in the small sample volumes. However, the 
model does not seem to support the ISI model derived from the AHP-question-
naire. According to the results of this study, there are no single RAI model that 
would fit the ISI model in all of the four case companies in both the past and the 
future timeframe simultaneously. This can also be confirmed by the SCA values 
of MAPE, RMSE, and MAD, as in all of the case companies the highest SCA val-
ues are determined for different RAI models. 
 
Based on the results from the case companies, the ISI model correlates well with 
the past and the future innovation status. However, the coupled OI strategy is 
problematic as it usually includes many types of OI strategies beneath it as de-
scribed in chapter 3.2. This means that the coupled OI strategy needs to be deter-
mined based on other specifications as well in addition to the individual innova-
tion strategy type values. 
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10. CONCLUSIONS 
 
Based on the results of this study there are no correlation between the RAI mod-
els derived from the resource allocation values and innovation strategy deter-
mined from the ISI model (RQ1). None of the specific RAI models individually 
support the ISI model based on the SCA. However, it is possible to evaluate the 
SCA based on the concurrence of all the four RAI and SCA models (RQ2). The 
past and the future ISI models did correlate with the WMT in all of the companies 
evaluated (RQ3). The results in the past and the future timeframe ISI were sub-
stantially different when compared to results obtained by Chesbrough & Bruns-
wicker (2013) in their OI survey, at least in the case of CC3 and CC4. 
 
In the survey performed by Chesbrough and Brunwicker (2013) for the medium-
high-technology and the high-technology industry MNEs, more than 82 % of 
these companies claimed to have been practicing OI in late 2012. In addition, on 
average 78 % of the respondents in that survey across industries claimed to have 
been practising OI by the end of 2012 (Chesbrough & Brunswicker 2013: 2-8). 
Accordingly, Lichtenthaler et al (2011) identified a group companies which ab-
sorb external technologies without transferring their own technologies to exter-
nal parties. A pharmaceutical company that relies on outside-in OI and collabo-
ration with other pharmaceutical and biotechnology companies was given as an 
example of this group. Within this group, the companies pursue also quite open 
inside-out OI strategy, but the implementation of this strategy is impeded by the 
NSH tendencies (Lichtenthaler et al 2011). The results from this specific study on 
the other hand correlates well with the results obtained in this study. 
 
In knowledge-intensive industries, as biotechnology and pharmaceutical indus-
try, OI seems to have demand in out-licensing and in-licensing business model 
to expand the current business opportunities and revenue of the companies. 
However, in this study, like described by Gassman & Enkel (2004) the inside-out 
OI strategy seems to play minor role compared to the outside-in OI strategy. This 
may be due to the lack of sufficient market place for this kind of transactions and 
because of the low capacity of venture capital compared to the other Nordic and 
European Economic Area (EAA). 
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Another important factor to the results can be the strategic use of IPR, which ac-
cording to Brem et al (2017) can have a negative effect to the revenue in SMEs 
that are engaging in OI operations. This can have affect to the use of inside-out 
OI strategy as it needs extensive use of internal IPR of the companies which also 
has relatively high transaction costs in case of SMEs and limits its use in the in-
side-out OI operations of the companies (Bogers, Bekkers & Grandstrand 2012: 
37-58). 
 
Despite the fact that OI will definitely make innovation more efficient in compa-
nies, it will also make innovation management more complex as well. Policy 
makers and science hubs plays an important role for providing a market place 
for inside-out and outside-in OI strategies. These hubs can work as a platform for 
coupled OI strategy as well. This progress has already taken place in EEA under 
the Horizon 2020 program for research and innovation that uses Open innova-
tion 2.0 paradigm approach. Previous research has also discovered that compa-
nies can choose one primary OI strategy, but also integrate some elements from 
other core OI strategies as well (Gassman & Enkel 2004). It has been shown that 
this study enables holistic measurement of innovation performance in companies 
using OI processes. It also provides tools for executives to evaluate the company's 
current and future emphasis of innovation and its management.   
 
The limitation of this study is that the developed model uses only four different 
innovation strategy types. Although, the closed innovation, inside-out, outside-
in, and coupled OI strategies represent the most recognized strategy types of OI, 
it leaves a lot room for interpretation for other subtypes of innovation, such as 
UI, RI, and DI. In addition, the AHP method was experienced as laborious to fill 
in context of the ICR, which was turn-out to be critical for the validity of the re-
sults. Nevertheless, the analytical side of this research can be considered as a 
good start for further research with more extensive group of research subjects. 
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10.1. Future research 
 
In the future, this novel method to evaluate the front-end innovation strategy 
should be validated in companies from various industries as well, such as me-
dium-high-technology, medium-low-technology, and low-technology manufac-
turing industries, ICT and other service industries, FMCG industry, and NGOs. 
The S-SMT and SMT should be used in addition to the WMT to further validate 
the method.  Although the innovation strategy of the companies is based on the 
attributes measured with the analytical model, it does not mean that other inno-
vation types are not present in the case companies analysed. In most cases all the 
types of innovation strategies exist in the company’s innovation strategy, but 
they are hard to detect and evaluate. 
 
The way how secondary innovation strategy types affect to the overall innova-
tion needs to be resolved and determined. This relationship should be evaluated 
in the future studies as well, as it might have substantial impact to the way how 
companies exploit the major innovation strategies in their innovation process. 
One approach to this would be to utilize the subattributes, that was used in the 
S&R-questionnaire, in the AHP-questionnaire as well. However, the limitations 
of this approach need to be considered as it can turn out to be too laborious to 
use, which will affect to the managerial implications of the model. 
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APPENDIX 4. Trend between past and future values of CFI, BCFI, SCFI, and NSCFI models in CC1. 
Subattribute CFI BCFI SCFI NSCFI 
T1: use of leading-edge technology WORSE WORSE WORSE SAME 
T2: use of external technology BETTER WORSE WORSE SAME 
T3: use of external product development ideas BETTER WORSE BETTER SAME 
T4: use of external intellectual property WORSE BETTER WORSE SAME 
T5: use of high-quality contract research BETTER WORSE WORSE SAME 
K1: cost of core competence WORSE WORSE WORSE WORSE 
K2: cost of publications BETTER WORSE BETTER BETTER 
K3: cost of intellectual property WORSE WORSE WORSE WORSE 
K4: cost for attending to alternative markets WORSE WORSE WORSE SAME 
K5: value of own intellectual property WORSE WORSE WORSE WORSE 
D1: time used for basic research WORSE BETTER WORSE WORSE 
D2: control of own intellectual property WORSE WORSE WORSE SAME 
D3: internal product development ideas WORSE BETTER BETTER BETTER 
D4: timing in current market WORSE WORSE WORSE SAME 
D5: own research & development WORSE BETTER BETTER WORSE 
C1: business model management WORSE BETTER WORSE WORSE 
C2: venture management WORSE BETTER BETTER SAME 
C3: outsourcing management WORSE BETTER WORSE SAME 
C4: expertise in other markets SAME BETTER WORSE WORSE 
C5 collaboration management WORSE BETTER WORSE WORSE 
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APPENDIX 5. Trend between past and future values of CFI, BCFI, SCFI, and NSCFI models in CC2. 
Subattribute CFI BCFI SCFI NSCFI 
T1: use of leading-edge technology WORSE WORSE WORSE SAME 
T2: use of external technology BETTER BETTER BETTER BETTER 
T3: use of external product development ideas WORSE WORSE WORSE WORSE 
T4: use of external intellectual property SAME SAME WORSE SAME 
T5: use of high-quality contract research SAME WORSE WORSE SAME 
K1: cost of core competence WORSE SAME SAME SAME 
K2: cost of publications BETTER WORSE WORSE WORSE 
K3: cost of intellectual property WORSE SAME SAME SAME 
K4: cost for attending to alternative markets BETTER SAME WORSE SAME 
K5: value of own intellectual property BETTER BETTER BETTER SAME 
D1: time used for basic research SAME WORSE WORSE BETTER 
D2: control of own intellectual property WORSE BETTER BETTER BETTER 
D3: internal product development ideas SAME SAME SAME SAME 
D4: timing in current market BETTER SAME WORSE SAME 
D5: own research & development WORSE BETTER BETTER BETTER 
C1: business model management WORSE SAME BETTER BETTER 
C2: venture management WORSE SAME BETTER SAME 
C3: outsourcing management SAME SAME WORSE SAME 
C4: expertise in other markets BETTER SAME SAME SAME 
C5 collaboration management WORSE SAME BETTER SAME 
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APPENDIX 6. Trend between past and future values of CFI, BCFI, SCFI, and NSCFI models in CC3. 
Subattribute CFI BCFI SCFI NSCFI 
T1: use of leading-edge technology BETTER WORSE WORSE SAME 
T2: use of external technology BETTER WORSE WORSE SAME 
T3: use of external product development ideas WORSE WORSE WORSE SAME 
T4: use of external intellectual property BETTER WORSE WORSE SAME 
T5: use of high-quality contract research WORSE WORSE WORSE SAME 
K1: cost of core competence BETTER WORSE WORSE SAME 
K2: cost of publications BETTER WORSE WORSE SAME 
K3: cost of intellectual property BETTER WORSE WORSE SAME 
K4: cost for attending to alternative markets BETTER BETTER BETTER BETTER 
K5: value of own intellectual property BETTER SAME WORSE SAME 
D1: time used for basic research BETTER WORSE WORSE WORSE 
D2: control of own intellectual property WORSE WORSE WORSE WORSE 
D3: internal product development ideas BETTER BETTER BETTER BETTER 
D4: timing in current market BETTER WORSE WORSE SAME 
D5: own research & development WORSE BETTER WORSE SAME 
C1: business model management BETTER BETTER BETTER BETTER 
C2: venture management BETTER WORSE WORSE SAME 
C3: outsourcing management BETTER WORSE WORSE SAME 
C4: expertise in other markets WORSE SAME WORSE SAME 
C5 collaboration management BETTER WORSE WORSE SAME 
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APPENDIX 7. Trend between past and future values of CFI, BCFI, SCFI, and NSCFI models in CC4. 
Subattribute CFI BCFI SCFI NSCFI 
T1: use of leading-edge technology BETTER BETTER BETTER BETTER 
T2: use of external technology WORSE WORSE WORSE SAME 
T3: use of external product development ideas SAME WORSE WORSE SAME 
T4: use of external intellectual property SAME WORSE WORSE SAME 
T5: use of high-quality contract research WORSE WORSE WORSE BETTER 
K1: cost of core competence BETTER BETTER BETTER BETTER 
K2: cost of publications WORSE WORSE WORSE WORSE 
K3: cost of intellectual property SAME SAME SAME SAME 
K4: cost for attending to alternative markets BETTER BETTER BETTER SAME 
K5: value of own intellectual property BETTER BETTER WORSE SAME 
D1: time used for basic research WORSE WORSE WORSE WORSE 
D2: control of own intellectual property WORSE BETTER SAME SAME 
D3: internal product development ideas BETTER WORSE WORSE WORSE 
D4: timing in current market WORSE BETTER WORSE SAME 
D5: own research & development SAME BETTER WORSE SAME 
C1: business model management BETTER SAME SAME SAME 
C2: venture management BETTER SAME SAME SAME 
C3: outsourcing management BETTER WORSE WORSE SAME 
C4: expertise in other markets BETTER WORSE WORSE SAME 
C5 collaboration management BETTER BETTER WORSE WORSE 
 
